{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:42:15Z","timestamp":1713177735189},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologie"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Das eyeWatch-System (EWS) (Rheon Medical, Lausanne, Schweiz) wurde als Glaukomdrainageimplantat (GDI) entwickelt, um den Augeninnendruck (IOD) pr\u00e4zise kontrollieren zu k\u00f6nnen und insbesondere in der fr\u00fchen postoperativen Phase die Entwicklung einer Hypotonie und ihrer Komplikationen zu verhindern.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Wir berichten \u00fcber die 1\u2011Jahres-Ergebnisse der mit dem EWS versorgten Patienten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Retrospektive Analyse von Augen, die eine EWS-Operation an der Universit\u00e4ts-Augenklinik Bonn, Deutschland, zwischen 05\/2021 und 09\/2022 erhielten.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Insgesamt wurden in dieser Studie\u00a05\u00a0Augen der ersten 5 konsekutiv mit dem EWS behandelten Patienten eingeschlossen. Der mittlere Augeninnendruck (IOD) lag pr\u00e4operativ bei 34,6\u202fmm\u202fHg (23\u201345\u202fmm\u202fHg) und reduzierte sich auf 12,2\u202fmm\u202fHg (9\u201318\u202fmm\u202fHg) mit einer durchschnittlichen Reduktion von 60\u202f%. Die lokale drucksenkende Therapie konnte von 2,8\u00a0Wirkstoffen pr\u00e4operativ (1 bis 4) auf 0,60 Wirkstoffe nach 1\u00a0Jahr gesenkt werden. Alle Patienten erreichten einen IOD-Zielwert von unter 21\u202fmm\u202fHg, davon 4\u00a0Patienten ohne weitere Medikation. Die Komplikationsrate war gering. Ein Patient musste 2\u2011mal chirurgisch revidiert werden, da der IOD nach der Operation auf \u00fcber 30\u202fmm\u202fHg erh\u00f6ht war und im Verlauf sich eine Tube-Exposition zeigte, sodass ein zweiter Spenderpatch aufgen\u00e4ht wurde. Derselbe Patient hatte nach einer cMRT-Untersuchung einen erh\u00f6hten IOD von mehr als 30\u202fmm\u202fHg. Bei diesem Patienten wurde mittels des eyeWatch Pen (EWP, Rheon Medical, Lausanne, Schweiz) eine Adjustierung des EWS durchgef\u00fchrt um den IOD wieder zu senken. IOD-Anpassungen mit dem EWP wurden bei 4 von 5\u00a0Patienten im ersten Jahr nach der Operation durchgef\u00fchrt, der mittlere IOD vor der Anpassung betrug 21,33\u202fmm\u202fHg (15\u201337\u202fmm\u202fHg) und wurde auf einen Mittelwert von 8,58\u202fmm\u202fHg (4\u201316\u202fmm\u202fHg) gesenkt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Das EWS senkt wirksam den IOD und die Menge ben\u00f6tigter drucksenkender Augentropfen. Mithilfe des EWP sind postoperative Anpassungen des IOD ohne weitere invasive Ma\u00dfnahmen m\u00f6glich.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00347-024-01994-x","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T14:02:01Z","timestamp":1708092121000},"page":"298-307","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Klinische Ergebnisse des eyeWatch-Systems: 1-Jahres-Outcome","Clinical results of the eyeWatch system: 1-year outcomes"],"prefix":"10.1007","volume":"121","author":[{"given":"Constance","family":"Weber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hundertmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Mercieca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,16]]},"reference":[{"key":"1994_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000458485","volume":"59","author":"AA Aref","year":"2017","unstructured":"Aref\u00a0AA, Gedde\u00a0SJ, Budenz\u00a0DL (2017) Glaucoma drainage implant surgery. Dev Ophthalmol 59:43\u201352","journal-title":"Dev Ophthalmol"},{"issue":"4","key":"1994_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1586\/17434440.3.4.509","volume":"3","author":"RS Ayyala","year":"2006","unstructured":"Ayyala\u00a0RS, Duarte\u00a0JL, Sahiner\u00a0N (2006) Glaucoma drainage devices: state of the art. Expert Rev Med Devices 3(4):509\u2013521","journal-title":"Expert Rev Med Devices"},{"issue":"5","key":"1994_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/IJG.0000000000001209","volume":"28","author":"S Roy","year":"2019","unstructured":"Roy\u00a0S et\u00a0al (2019) Initial clinical results of the eyeWatch: a\u00a0new adjustable glaucoma drainage device used in refractory glaucoma surgery. J\u00a0Glaucoma 28(5):452\u2013458","journal-title":"J Glaucoma"},{"issue":"5","key":"1994_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/IJG.0000000000001471","volume":"29","author":"S Roy","year":"2020","unstructured":"Roy\u00a0S et\u00a0al (2020) Comparison between the eyeWatch device and the ahmed valve in refractory glaucoma. J\u00a0Glaucoma 29(5):401\u2013405","journal-title":"J Glaucoma"},{"issue":"10","key":"1994_CR5","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.ophtha.2016.06.035","volume":"123","author":"PG Christakis","year":"2016","unstructured":"Christakis\u00a0PG et\u00a0al (2016) The ahmed versus baerveldt study: five-year treatment outcomes. Ophthalmology 123(10):2093\u20132102","journal-title":"Ophthalmology"},{"key":"1994_CR6","doi-asserted-by":"publisher","first-page":"xii","DOI":"10.1016\/j.ajo.2015.12.031","volume":"163","author":"EJ Rockwood","year":"2016","unstructured":"Rockwood\u00a0EJ (2016) The Ahmed Baerveldt Comparison (ABC) study: long-term results, successes, failures, and complications. Am J Ophthalmol 163:xii\u2013xiv","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1994_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/archopht.116.5.571","volume":"116","author":"QH Nguyen","year":"1998","unstructured":"Nguyen\u00a0QH, Budenz\u00a0DL, Parrish\u00a0RK 2nd (1998) Complications of baerveldt glaucoma drainage implants. Arch Ophthalmol 116(5):571\u2013575","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1994_CR8","doi-asserted-by":"publisher","first-page":"64","DOI":"10.5005\/jp-journals-10078-1276","volume":"14","author":"ET Detorakis","year":"2020","unstructured":"Detorakis\u00a0ET et\u00a0al (2020) eyeWatch\u2122 system combined with non-plated intraorbital tube insertion for the management of refractory glaucoma: a\u00a0case series. J\u00a0Curr Glaucoma Pract 14(2):64\u201367","journal-title":"J Curr Glaucoma Pract"},{"issue":"11","key":"1994_CR9","doi-asserted-by":"publisher","first-page":"7520","DOI":"10.1167\/iovs.14-14563","volume":"55","author":"A Villamarin","year":"2014","unstructured":"Villamarin\u00a0A et\u00a0al (2014) In vivo testing of a\u00a0novel adjustable glaucoma drainage device. Invest Ophthalmol Vis Sci 55(11):7520\u20137524","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1994_CR10","doi-asserted-by":"publisher","first-page":"Np79","DOI":"10.1177\/1120672120973617","volume":"32","author":"S Roy","year":"2022","unstructured":"Roy\u00a0S et\u00a0al (2022) MRI after successful eyeWatch(TM) implantation. Eur J Ophthalmol 32(1):Np79\u2013np82","journal-title":"Eur J Ophthalmol"}],"container-title":["Die Ophthalmologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-01994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00347-024-01994-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-024-01994-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T10:05:36Z","timestamp":1713175536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00347-024-01994-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1994"],"URL":"https:\/\/doi.org\/10.1007\/s00347-024-01994-x","relation":{},"ISSN":["2731-720X","2731-7218"],"issn-type":[{"value":"2731-720X","type":"print"},{"value":"2731-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]},"assertion":[{"value":"19 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"C.\u00a0Weber, S.\u00a0Hundertmark, F.G.\u00a0Holz und K.\u00a0Mercieca geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}